149 related articles for article (PubMed ID: 36093514)
1. Significant efficacy of paclitaxel plus carboplatin (TP) as a neoadjuvant regimen for metaplastic squamous cell carcinoma of the breast: a rare case report and literature review.
Chen B; Jiang Y; Luo C; Bao Y; Tan N; Li T; Cheng X; Lv J
Transl Cancer Res; 2022 Aug; 11(8):2953-2959. PubMed ID: 36093514
[TBL] [Abstract][Full Text] [Related]
2. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
3. A Case Report of a Rare ER+, PR- Pure Metaplastic Breast Squamous Cell Carcinoma with HER2 Overexpression.
Adam SA; Kamaruddin KN; Abd Shukor N; Abdullah Suhaimi SN; Ismail F; Md Yasin M
Am J Case Rep; 2023 Dec; 24():e941448. PubMed ID: 38048289
[TBL] [Abstract][Full Text] [Related]
4. A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel.
Noro A; Ishitobi M; Hanamura N; Kashikura Y; Yamashita M; Kozuka Y; Saito K; Mizuno T; Ogawa T
Am J Case Rep; 2022 Jan; 23():e935035. PubMed ID: 35017459
[TBL] [Abstract][Full Text] [Related]
5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
6. The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy.
Flores-Balcázar CH; Castro-Alonso FJ; Hernández-Barragán TP; Delgado-de la Mora J; Daidone A; Trejo-Durán GE
Oncology (Williston Park); 2021 Mar; 35(3):139-143. PubMed ID: 33818049
[TBL] [Abstract][Full Text] [Related]
7. HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report.
Tateishi K; Kiyoi M; Miyasaka M; Kawaji M; Nakanishi H; Furuta Y; Nishimatsu M; Takahashi Y; Nishikawa M; Nishimura Y
Case Rep Oncol; 2023; 16(1):1482-1488. PubMed ID: 38028581
[TBL] [Abstract][Full Text] [Related]
8. SOX10 - A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma.
Qi J; Hu Z; Xiao H; Liu R; Guo W; Yang Z; Ma K; Su S; Tang P; Zhou X; Zhou J; Wang K
Cancer Manag Res; 2020; 12():4039-4044. PubMed ID: 32547236
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.
Chen XS; Nie XQ; Chen CM; Wu JY; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Ann Oncol; 2010 May; 21(5):961-7. PubMed ID: 20211870
[TBL] [Abstract][Full Text] [Related]
11. The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case.
Ding J; Hu P; Chen J; Wu X; Cao Y
Oncoscience; 2016; 3(9-10):268-274. PubMed ID: 28050577
[TBL] [Abstract][Full Text] [Related]
12. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
13. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
14. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
[TBL] [Abstract][Full Text] [Related]
16. A Case of Carcinosarcoma of the Breast Presenting as Inflammatory Carcinoma and Review of the Literature.
Neelamraju Lakshmi H; Saini D; Om P; Verma N
Cureus; 2020 Aug; 12(8):e10104. PubMed ID: 33005523
[TBL] [Abstract][Full Text] [Related]
17. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
Tampaki EC; Tampakis A; Alifieris CE; Krikelis D; Pazaiti A; Kontos M; Trafalis DT
Clin Drug Investig; 2018 Jul; 38(7):639-648. PubMed ID: 29744672
[TBL] [Abstract][Full Text] [Related]
19. Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.
Yao L; Zhang J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Chin J Cancer Res; 2015 Dec; 27(6):553-61. PubMed ID: 26752929
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of Concurrent Follicular Lymphoma and Triple-Negative Breast Cancer Using Rituximab Plus Nab-Paclitaxel and Cisplatin: A Case Report and Literature Review.
Zhu Z; Zhou N; Yu S; Gao X; Cheng X; Wang Y; Bai C
Onco Targets Ther; 2023; 16():905-911. PubMed ID: 37933332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
